BioPharma Credit PLC announced that it, through its fully owned subsidiary, together with BioPharma Credit Investments V (Master) LP has entered into an amended and restated loan agreement with Epizyme, Inc. dated 3 November 2020. As part of this amendment, the Company will invest an additional USD 75 million in the Epizyme loan. Under the original terms of the loan agreement, executed in November 2019, Epizyme borrowed USD 70 million in three tranches and the Company previously invested USD 35 million with BioPharma-V investing the USD 35 million balance. The original USD 70 million loan will mature in November 2024 and bears interest at LIBOR plus 7.75% per annum along with a one-time additional consideration of 2.00% of the total loan amount. In addition, the facility was expandable by up to USD 300 million, subject to mutual agreement between the Lenders and Epizyme after approval of tazemetostat for the treatment of follicular lymphoma. On 23 January 2020, TAZVERIK® was granted accelerated approval from the U.S. Food and Drug Administration for the treatment of patients with epithelioid sarcoma and on 18 June 2020 TAZVERIK received accelerated approval from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma. The amendment increases the aggregate principal amount of the loan to Epizyme to USD 220 million through a USD 150 million fourth tranche, which the parties expect to be drawn in full on 18 November 2020. The Company will invest USD 75 million of the USD 150 million Tranche D and BioPharma-V will invest the USD 75 million balance. Tranche D will have the same fees and coupon as the earlier tranches, will be secured by the same collateral as the earlier tranches, and will mature in November 2026 after eight equal amortization payments beginning in February 2025. As part of the amendment, the amortization terms of the initial USD 70 million advanced in the first three tranches were changed from eight equal quarterly payments starting in February 2023 to four equal quarterly payments starting in February 2024. Following the expected Tranche D closing, the facility will remain expandable by up to an additional USD 150 million, subject to mutual agreement between the Lenders and Epizyme.